Component
The CYP2C8*3 variant allele
The CYP2C8*3 variant allele. Species, exposure and limitations are retained in each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What it acts on
The CYP2C8*3 allele influenced the pharmacokinetics of R-ibuprofen in a gene-dose manner, with plasma half-life after 400 milligrams of 2.0 hours in CYP2C8*1/*1, 4.2 hours in *1/*3 and 9.0 hours in *3/*3 individuals, alongside significant trends in area under the curve and clearance, and the allele frequency of 0.17 in this Spanish Caucasian population was higher than reported elsewhere and was associated with CYP2C9*2 at 2.4-fold the expected frequency.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/ibuprofen-research/15606441.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "60cffa777fc0b9881548e974376299ec7e970c2785586766150896cbf0561af9", "start_char": 0, "end_char": 1795, "text_sha256": "60cffa777fc0b9881548e974376299ec7e970c2785586766150896cbf0561af9"}
- experimental_model
- Genotype screening of 355 Spanish Caucasians with pharmacokinetics in 25 individuals grouped by CYP2C8 genotype
- exposure
- 400 milligrams ibuprofen, with R-ibuprofen disposition followed by genotype
- limitations
- A clear gene-dose effect on the enantiomer that CYP2C9 does not handle. One population, and 25 individuals across the genotype groups.
- nutrient_topic
- Ibuprofen research collection; topical membership is not evidence of a direct clinical effect, and the racemate is recorded separately from each of its two enantiomers. · Ibuprofen
- organism
- Human
- plain_language
- A common variant makes the R half linger more than four times as long.
- primary_references
- [ibu-p15606441] The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. (2005). https://pubmed.ncbi.nlm.nih.gov/15606441/ DOI: 10.1111/j.1365-2125.2004.02183.x
- tissue_or_cell_type
- Plasma
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Genotype screening of 355 Spanish Caucasians with pharmacokinetics in 25 individuals grouped by CYP2C8 genotype · source_derived_draft · unverified_draft
### ibu-cyp2c8-and-the-r-hand The CYP2C8*3 allele influenced the pharmacokinetics of R-ibuprofen in a gene-dose manner, with plasma half-life after 400 milligrams of 2.0 hours in CYP2C8*1/*1, 4.2 hours in *1/*3 and 9.0 hours in *3/*3 individuals, alongside significant trends in area under the curve and clearance, and the allele frequency of 0.17 in this Spanish Caucasian population was higher than reported elsewhere and was associated with CYP2C9*2 at 2.4-fold the expected frequency. Condition category: normal nutrient_topic: Ibuprofen research collection; topical membership is not evidence of a direct clinical effect, and the racemate is recorded separately from each of its two enantiomers. plain_language: A common variant makes the R half linger more than four times as long. organism: Human tissue_or_cell_type: Plasma experimental_model: Genotype screening of 355 Spanish Caucasians with pharmacokinetics in 25 individuals grouped by CYP2C8 genotype limitations: A clear gene-dose effect on the enantiomer that CYP2C9 does not handle. One population, and 25 individuals across the genotype groups. exposure: 400 milligrams ibuprofen, with R-ibuprofen disposition followed by genotype evidence_span: {"source_cache": "artifacts/ibuprofen-research/15606441.abstract.txt", "locator": "Indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "60cffa777fc0b9881548e974376299ec7e970c2785586766150896cbf0561af9", "start_char": 0, "end_char": 1795, "text_sha256": "60cffa777fc0b9881548e974376299ec7e970c2785586766150896cbf0561af9"} [ibu-p15606441] The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. (2005). https://pubmed.ncbi.nlm.nih.gov/15606441/ DOI: 10.1111/j.1365-2125.2004.02183.x
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.